History of U.S. military contributions to the study of viral encephalitis

Military Medicine

Volumn 170, Issue 4 SUPPL., 2005, Pages 92-105

  Hoke Jr , Charles H ^a,b  

^a U S ARMY MEDICAL RESEARCH AND MATERIEL COMMAND   (United States)

^b GENERAL DYNAMICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA VIRUS VACCINE; DEXAMETHASONE; DNA VACCINE; ENCEPHALITIS VACCINE; HEPATITIS A VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INACTIVATED VACCINE; JAPANESE ENCEPHALITIS VACCINE; LIVE VACCINE; RECOMBINANT VACCINE; TICK BORNE ENCEPHALITIS VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; WEST NILE VACCINE;

CLINICAL TRIAL; CONFERENCE PAPER; EASTERN EQUINE ENCEPHALITIS; ENCEPHALITIS; ENCEPHALOMYELITIS; EPIDEMIC ENCEPHALITIS; HUMAN; MILITARY MEDICINE; NONHUMAN; PATHOGENESIS; RABIES; TICK BORNE ENCEPHALITIS; UNITED STATES; VIRUS ENCEPHALITIS; VIRUS INFECTION; WESTERN EQUINE ENCEPHALITIS;

EID: 17444398954     PISSN: 00264075     EISSN: None     Source Type: Journal    
DOI: 10.7205/MILMED.170.4S.92     Document Type: Conference Paper

References (233)

1. Gadjusek DC: Autobiography. Available at http://nobelprize.org/medicine/ laureates/ 1976/gajdusek-autobio.html: accessed December 2004.
2. McAda PC, Mason PW, Schmaljohn CS, Dalrymple JM, Mason TL, Fournier MJ: Partial nucleotide sequence of the Japanese encephalitis virus genome. Virology 1987; 158: 348-60.
3. Tsarev SA, Sanders ML, Vaughn DW, Innis BL: Phylogenetic analysis suggests only one serotype of Japanese encephalitis virus. Vaccine 2000; 18(Suppl 2): 36-43.
4. Sumiyoshi H, Tignor GH, Shope RE: Characterization of a highly attenuated Japanese encephalitis virus generated from molecularly cloned cDNA. J Infect Dis 1995; 171: 1144-51.
5. Leake CJ, Burke DS, Nisalak A, Hoke CH: Isolation of Japanese encephalitis virus from clinical specimens using a continuous mosquito cell line. Am J Trop Med Hyg 1986; 35: 1045-50.
6. Halstead SB, Grosz CR: Subclinical Japanese encephalitis. 1. Infection of Americans with limited residence in Korea. Am J Hyg 1962; 75: 190-201.
7. Hullinghorst RL, Burns KF, Choi YT, Whatley LR: Japanese B encephalitis in Korea; the epidemic of 1949. JAMA 1951; 145: 460-6.
8. Lincoln AF, Siverson SE: Acute phase of Japanese B encephalitis; two hundred and one cases in American soldiers, Korea, 1950. JAMA 1952; 150: 268-73.
9. Perez-Pina F, Merikangas UR: Japanese B encephalitis in an American soldier returning from Korea. N Engl J Med 1953; 249: 531-2.
10. Benenson MW, Top FH, Gresso W, Ames CW, Altstatt LB: The virulence to man of Japanese encephalitis virus in Thailand. Am J Trop Med Hyg 1975; 24: 974-80.
11. Buescher EL, Scherer WF: Ecologic studies of Japanese encephalitis virus in Japan. IX. Epidemiologic correlations and conclusions Am J Trop Med Hyg 1959; 8: 719-22.
12. Buescher EL, Scherer WF, Grossbert SE, Chanock RM, Philpot V: Immunologic studies of Japanese encephalitis virus in Japan. 1. Antibody responses following overt infection of man. J Immunol 1959; 83: 582-93.
13. Buescher EL, Scherer WF, McClure HE, et al: Ecologic studies of Japanese encephalitis virus in Japan. IV. Avian infection Am J Trop Med Hyg 1959; 8: 678-88.
14. Buescher EL, Scherer WF, Rosenbert MZ, Gresser I, Hardy JL, Bullock HR: Ecologic studies of Japanese encephalitis virus in Japan. II. Mosquito infection Am J Trop Med Hyg 1959; 8: 651-64.
15. Buescher EL, Scherer WF, Rosenbert MZ, Kutner LJ, McClure HE: Immunologic studies of Japanese encephalitis virus in Japan. IV. Maternal antibody in birds. J Immunol 1959; 83: 614-19.
16. Buescher EL, Scherer WF, Rosenbert MZ, McClure HE: Immunologic studies of Japanese encephalitis virus in Japan. III. Infection and antibody responses of birds. J Immunol 1959; 83: 605-13.
17. Sabin AB: Search for virus of Japanese B encephalitis in various arthropods collected in Japan in 1946-1947. Am J Hyg 1950; 51: 36-62.
18. Sasa M, Sabin AB: Ecological studies on the mosquitoes of Okayama in relation to the epidemiology of Japanese B encephalitis. Am J Hyg 1950; 51: 21-35.
19. Scherer WF, Buescher EL: Ecologic studies of Japanese encephalitis virus in Japan. 1. Introduction Am J Trop Med Hyg 1959; 8: 644-50.
20. Scherer WF, Buescher EL, Flemings MB, Noguchi A, Scanlon J: Ecologic studies of Japanese encephalitis virus in Japan. III. Mosquito factors Zootropism and vertical flight of Culex tritaeniorhynchus with observations on variations in collections from animal-baited traps in different habitats Am J Trop Med Hyg 1959; 8: 665-77.
21. Scherer WF, Buescher EL, McClure HE: Ecologic studies of Japanese encephalitis virus in Japan. V. Avian factors. Am J Trop Med Hyg 1959; 8: 689-97.
22. Scherer WF, Buescher EL, Southam CM, Flemings MB, Noguchi A: Ecologic studies of Japanese encephalitis virus in Japan. VIII. Survey for infection of wild rodents. Am J Trop Med Hyg 1959; 8: 716-8.
23. Edelman R, Nisalak A, Pariyanonda A, Udomsakdi S, Johnsen DO: Immunoglobulin response and viremia in dengue-vaccinated gibbons repeatedly challenged with Japanese encephalitis virus. Am J Epidemiol 1973; 97: 208-18.
24. Edelman R, Pariyanonda A: Human immunoglobulin M antibody in the sero-diagnosis of Japanese encephalitis virus infections. Am J Epidemiol 1973; 98: 29-38.
25. Edelman R, Schneider RJ, Chieowanich P, Pompibul R, Voodhikul P: The effect of dengue virus infection on the clinical sequelae of Japanese encephalitis: a one year follow-up study in Thailand. Southeast Asian J Trop Med Public Health 1975; 6: 308-15.
26. Edelman R, Schneider RJ, Vejjajiva A, Pornpibul R, Voodhikul P: Persistence of virus-specific IgM and clinical recovery after Japanese encephalitis. Am J Trop Med Hyg 1976; 25: 733-8.
27. Could DJ, Edelman R, Grossman RA, Nisalak A, Sullivan MF: Study of Japanese encephalitis virus in Chiangmai Valley, Thailand. IV Vector studies. Am J Epidemiol 1974; 100: 49-56.
28. Grossman RA, Edelman R, Chiewanich P, Voodhikul P, Siriwan C: Study of Japanese encephalitis virus in Chiangmai Valley, Thailand. II Human clinical infections. Am J Epidemiol 1973; 98: 121-32.
29. Grossman RA, Edelman R, Could DJ: Study of Japanese encephalitis virus in Chiangmia Valley, Thailand. VI Summary and conclusions. Am J Epidemiol 1974; 100: 69-76.
30. Grossman RA, Edelman R, Willhight M, Pantuwatana S, Udomsakdi S: Study of Japanese encephalitis virus in Chiangmai Valley, Thailand. III. Human seroepidemiology and inapparent infections. Am J Epidemiol 1973; 98: 133-49.
31. Johnsen DO, Edelman R, Grossman RA, Muangman D, Pomsdhit J, Gould DJ: Study of Japanese encephalitis virus in Chiangmia Valley, Thailand. V. Animal infections. Am J Epidemiol 1974; 100: 57-68.
32. Leake CJ, Ussery MA, Nisalak A, Hoke CH, Andre RG, Burke DS: Virus isolations from mosquitoes collected during the 1982 Japanese encephalitis epidemic in northern Thailand. Trans R Soc Trop Med Hyg 1986; 80: 831-7.
33. Muangman D, Edelman R, Sullivan MJ: Experimental transmission of Japanese encephalitis virus by Culexjuscocephala. Am J Trop Med Hyg 1972; 21: 482-6.
34. Schneider RJ, Firestone MH, Edelman R, Chieowanich P, Pornpibul R: Clinical sequelae after Japanese encephalitis: a one year follow-up study in Thailand. Southeast Asian J Trop Med Public Health 1974; 5: 560-8.
35. Simasathien P, Rohitayodhin S, Nisalak A, Singharaj P, Halstead SB, Russell PK: Recovery of Japanese encephalitis virus from wild caught mosquitoes in Thailand. Southeast Asian J Trop Med Public Health 1972; 3: 52-4.
36. Burke DS, Ussery MA, Elwell MR, Nisalak A, Leake C, Laorakpongse T: Isolation of Japanese encephalitis virus strains from sentinel pigs in northern Thailand, 1982. Trans R Soc Trop Med Hyg 1985; 79: 420-1.
37. Burke DS, Tingpalapong M, Ward GS, Andre R, Leake CJ: Intense transmission of Japanese encephalitis virus to pigs in a region free of epidemic encephalitis. Southeast Asian J Trop Med Public Health 1985; 16: 199-206.
38. Gingrich JB, Nisalak A, Latendresse JR, et al: Japanese encephalitis virus in Bangkok: factors influencing vector infections in three suburban communities. J Med Entomol 1992; 29: 436-42.
39. Gingrich JB, Nisalak A, Latendresse JR, et al: A longitudinal study of Japanese encephalitis in suburban Bangkok, Thailand. Southeast Asian J Trop Med Public Health 1987; 18: 558-66.
40. Henderson A, Leake CJ, Burke DS: Japanese encephalitis in Nepal. Lancet 1983; 2: 1359-60.
41. Basnyat B, Zimmerman MD, Shrestha Y, Scott RM, Endy TP: Persistent Japanese encephalitis in Kathmandu: the need for immunization. J Travel Med 2001; 8: 270-1.
42. Burkett DA, Lee WJ, Lee KW, et al: Late season commercial mosquito trap and host seeking activity evaluation against mosquitoes in a malarious area of the Republic of Korea. Korean J Parasitol 2002; 40: 45-54.
43. Chhour YM, Ruble G, Hong R, et al: Hospital-based diagnosis of hemorrhagic fever, encephalitis, and hepatitis in Cambodian children. Emerg Infect Dis 2002; 8: 485-9.
44. Endy TP, Nisalak A: Japanese encephalitis virus: ecology and epidemiology. Curr Top Microbiol Immunol 2002; 267: 11-48.
45. Shultz GW, Hayes CG: Ecology of mosquitoes (Diptera: Culicidae) at a site endemic with Japanese encephalitis on Luzon, Republic of the Philippines. Southeast Asian J Trop Med Public Health 1993; 24: 157-64.
46. Turell MJ, O'Guinn ML, Wasieloski LP, et al: Isolation of Japanese encephalitis and Getah viruses from mosquitoes (Diptera: Culicidae) collected near Camp Greaves, Gyonggi Province, Republic of Korea, 2000. J Med Entomol 2003; 40: 580-4.
47. Vaughn DW, Hoke CH: The epidemiology of Japanese encephalitis: prospects for prevention. Epidemiol Rev 1992; 14: 197-221.
48. Zimmerman MD, Scott RM, Vaughn DW, Rajbhandari S, Nisalak A, Shrestha MP: Short report: an outbreak of Japanese encephalitis in Kathmandu, Nepal. Am J Trop Med Hyg 1997; 57: 283-4.
49. Sabin AB, Buscher EL: Unique physico-chemical properties of Japanese B encephalitis virus hemagglutinin. Proc Soc Exp Biol Med 1950; 74: 222-30.
50. Russell PK, Nisalak A: Dengue virus identification by the plaque reduction neutralization test. J Immunol 1967; 99: 291-6.
51. Burke DS, Chatiyanonda K, Anandrik S, Nakomsri S, Nisalak A, Hoke CH: Improved surveillance of Japanese encephalitis by detection of virus-specific IgM in desiccated blood specimens. Bull World Health Organ 1985; 63: 1037-42.
52. Burke DS, Nisalak A: Detection of Japanese encephalitis virus immunoglobulin M antibodies in serum by antibody capture radioimmunoassay. J Clin Microbiol 1982; 15: 353-61.
53. Burke DS, Nisalak A, Hoke CH: Field trial of a Japanese encephalitis diagnostic kit. J Med Virol 1986; 18: 41-9.
54. Burke DS, Nisalak A, Lorsomrudee W, Ussery MA, Laorpongse T: Virus-specific antibody-producing cells in blood and CSF in acute Japanese encephalitis. J Med Virol 1985; 17: 283-92.
55. Burke DS, Nisalak A, Ussery MA: Antibody capture immunoassay detection of Japanese encephalitis virus immunoglobulin M and G antibodies in CSF. J Clin Microbiol 1982; 16: 1034-42.
56. Burke DS, Nisalak A, Ussery MA, Laorakpongse T, Chantavibul S: Kinetics of IgM and IgG responses to Japanese encephalitis virus in human serum and CSF, J Infect Dis 1985; 151: 1093-9.
57. Burke DS, Tingpalapong M, Elwell MR, Paul PS, Van Deusen RA: Japanese encephalitis virus immunoglobulin M antibodies in porcine sera. Am J Vet Res 1985; 46: 2054-7.
58. Cuzzubbo AJ, Endy TP, Vaughn DW, et al: Evaluation of a new commercially available immunoglobulin M capture ELISA for diagnosis of Japanese encephalitis infections. J Clin Microbiol 1999; 37: 3738-41.
59. Innis BL, Nisalak A, Nimmannitya S, et al: An ELISA to characterize dengue infections where dengue and Japanese encephalitis co-circulate. Am J Trop Med Hyg 1989; 40: 418-27.
60. Henchal EA, Narupiti S, McAda P, et al: Rapid detection of dengue and Japanese encephalitis viruses using nucleic acid hybridization. In Proceedings of the Four Australian Arbovirus Symposium, pp 112-18. Edited by St. George TD, Kay BH, Blok J. Sydney, Academic Press, 1987.
61. Puri B, Henchal EA, Burans J, et al: A rapid method for detection and identification of flaviviruses by polymerase chain reaction and nucleic acid hybridization. Arch Virol 1994; 134: 29-37.
62. Leake CJ, Johnson RT: The pathogenesis of Japanese encephalitis virus in Culex tritaeraorhynchus mosquitoes. Trans R Soc Trop Med Hyg 1987; 81: 681-5.
63. Hase T, Summers PL, Dubois DR: Ultrastructural changes of mouse brain neurons infected by Japanese encephalitis virus. Int J Exp Pathol 1990; 71: 493-505.
64. Johnson RT, Burke DS, Elwell M, et al: Japanese encephalitis: immunocytochemical studies of viral antigen and inflammatory cells in fatal cases. Ann Neurol 1985; 18: 567-73.
65. Johnson RT, Intralawan P, Puapanwatton S: Japanese encephalitis: identification of inflammatory cells in CSF. Ann Neurol 1986; 20: 691-5.
66. Burke DS, Lorsomrudee W, Leake CJ, et al: Fatal outcome in Japanese encephalitis. Am J Trop Med Hyg 1985; 34: 1203-10.
67. Libraty DH, Nisalak A, Endy TP, Suntayakom S, Vaughn DW, Innis BL: Clinical and immunological risk factors for severe disease in Japanese encephalitis. Trans R Soc Trop Med Hyg 2002; 96: 173-8.
68. Hoke CH, Vaughn DW, Nisalak A, et al: Effect of high-dose dexamethasone on the outcome of acute encephalitis due to Japanese encephalitis virus. J Infect Dis 1992; 165: 631-7.
69. Burke DS, Morill JC: Levels of Interferon in the plasma and CSF of patients with acute Japanese encephalitis. J Infect Dis 1987; 155: 797-9.
70. Solomon T, Dung NM, Wills B, et al: Interferon α-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial. Lancet 2003; 361: 821-6.
71. Sabin AB: Epidemic encephalitis in military personnel; isolation of Japanese B virus on Okinawa in 1945: serologic diagnosis, clinical manifestations, epidemic aspects and use of mouse brain vaccine. JAMA 1947; 133: 281-93.
72. Sabin AB, Tigertt WD: Evaluation of Japanese B encephalitis vaccine. 1. General background and methods. Am J Hyg 1956; 63: 217-27.
73. Brown AE, Nitayaphan S: Foundations for a Phase III human immunodeficiency virus vaccine trial: a decade of Thai-U.S. Army collaborative research. MilK Med 2004; 169: 588-93.
74. Innis BL, Snitbhan R, Kunasol P, et al: Protection against hepatitis A by an inactivated vaccine. JAMA 1994; 271: 1328-34.
75. Hoke CH, Nisalak A, Sangawhipa N, et al: Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med 1988; 319: 608-14.
76. Brandt WE: From the World Health Organization: development of dengue and Japanese encephalitis vaccines. J Infect Dis 1990; 162: 577-83.
77. Defraites RF, Gambel JM, Hoke CH, et al: Japanese encephalitis vaccine (inactivated, BIKEN) in U.S. soldiers: immunogenicity and safety of vaccine administered in two dosing regimens Am J Trop Med Hyg 1999; 61: 288-93.
78. Gambel JM, DeFraites R, Hoke C, et al: Japanese encephalitis vaccine: persistence of antibody up to 3 years after a three-dose primary series. J Infect Dis 1995; 171: 1074.
79. Sanchez JL, Hoke CH, McCown J, et al: Further experience with Japanese encephalitis vaccine. Lancet 1990; 335: 972-3.
80. Mason PW, Dalrymple JM, Gentry MK, et al: Molecular characterization of a neutralizing domain of the Japanese encephalitis virus structural glycoprotein. J Gen Virol 1989; 70: 2037-49.
81. Mason PW, McAda PC, Dalrymple JM, Fournier MJ, Mason TL: Expression of Japanese encephalitis virus antigens in Escherichia coli. Virology 1987; 158: 361-72.
82. McCown J, Cochran M, Putnak R, et al: Protection of mice against lethal Japanese encephalitis with a recombinant baculovirus vaccine. Am J Trop Med Hyg 1990; 42: 491-9.
83. Sumiyoshi H, Hoke CH, Trent DW: Infectious Japanese encephalitis virus RNA can be synthesized from in vitro-Ugated cDNA templates. J Virol 1992; 66: 5425-31.
84. Myint KS, Raengsakulrach B, Young GD, et al: Production of lethal infection that resembles fatal human disease by intranasal inoculation of macaques with Japanese encephalitis virus. Am J Trop Med Hyg 1999; 60: 338-42.
85. Raengsakulrach B, Nisalak A, Gettayacamin M, et al: An intranasal challenge model for testing Japanese encephalitis vaccines in rhesus monkeys. Am J Trop Med Hyg 1999; 60: 329-37.
86. Kanesa-Thasan N, Smucny JJ, Hoke CH, et al: Safety and immunogenicity of NWAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus-poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans. Vaccine 2000; 19: 483-91.
87. Konishi E, Kurane I, Mason PW, et al: Induction of Japanese encephalitis virus-specific cytotoxic T lymphocytes in humans by poxvirus-based JE vaccine candidates. Vaccine 1998; 16: 842-9.
88. + cytotoxic T lymphocytes in mice. Virology 1997; 227: 353-60.
89. Raengsakulrach B, Nisalak A, Gettayacamin M, et al: Safety, immunogenicity, and protective efficacy of NWAC-JEV and ALVAC-JEV recombinant Japanese encephalitis vaccines In rhesus monkeys. Am J Trop Med Hyg 1999; 60: 343-9.
90. Sumiyoshi H, Hoke CH: Infectious Japanese encephalitis virus cDNA clones that produce highly attenuated recombinant Japanese encephalitis virus and vaccines thereof. U.S. Patent 5,736,148. April 7, 1998. Available at www.uspto.gov; accessed December 2004.
91. Bista MB, Banerjee MK, Shin SH, et al: Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study. Lancet 2001; 358: 791-5.
92. Eckels KH, Yu YX, Dubois DR, Marchette NJ, Trent DW, Johnson AJ: Japanese encephalitis virus live-attenuated vaccine, Chinese strain SA14-14-2; adaptation to primary canine kidney cell cultures and preparation of a vaccine for human use. Vaccine 1988; 6: 513-8.
93. Halstead SB: Vaccines for Japanese encephalitis. Lancet 1996; 348: 341.
94. Halstead SB, Jacobson J: Japanese encephalitis. Adv Virus Res 2003; 61: 103-38.
95. Hase T, Dubois DR, Summers PL, Downs MB, Ussery MA: Comparison of replication rates and pathogenicities between the SA14 parent and SA14-14-2 vaccine strains of Japanese encephalitis virus in mouse brain neurons. Arch Virol 1993; 130: 131-43.
96. Hennessy S, Liu Z, Tsai TF, et al: Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. Lancet 1996; 347: 1583-6.
97. Tsai TF, Yu YX, Jia LL, et al: Immunogenicity of live attenuated SA14-14-2 Japanese encephalitis vaccine-a comparison of 1- and 3-month immunization schedules. J Infect Dis 1998; 177: 221-3.
98. Armed Forces Epidemiological Board: Commercial scale development of Japanese B encephalitis vaccine (memo dated June 28, 1965). Available at www. ha.osd.mil/afeb/1965/1965-16.pdf; accessed December 2004.
99. Darwish MA, Hammon WM: Studies on Japanese B encephalitis virus vaccines from tissue culture. 8. Formalin inactivated OCT-wild strain vaccine. J Immunol 1966; 97: 506-11.
100. Darwish MA, Hammon WM: Studies on Japanese B encephalitis virus vaccine from tissue culture. VI. Development of a hamster kidney tissue culture inactivated vaccine for man. 4. Preparation and characterization of vaccine lot for human trial. Am J Trop Med Hyg 1966; 15: 765-8.
101. Darwish MA, Hammon WM: Japanese B encephalitis virus vaccines from tissue culture. VII. Formalin inactivated Nakayama strain vaccine. Proc Soc Exp Biol Med 1966; 122: 813-6.
102. Darwish MA, Hammon WM, Sather GE: Studies on Japanese B encephalitis virus vaccines from tissue culture. IX. Human response to a hamster-kidney tissue-culture inactivated vaccine Am J Trop Med Hyg 1967; 16: 364-70.
103. French GR, Hammon WM: Studies on Japanese B encephalitis virus vaccines from tissue culture. X. Characterization of a 37°C passage line attenuated strain of OCT-541 virus. J Immunol 1969; 103: 1260-7.
104. Hammon WM, Rohitayodhin S, Rhim JS: Studies on Japanese B encephalitis virus vaccines from tissue culture. IV. Preparation and characterization of pool of attenuated OCT-541 line for human vaccine trial. J Immunol 1963; 91: 295-305.
105. Hammon WM, Sather GE: Passive immunity for arbovirus infection. I. Artificially induced prophylaxis in man and mouse for Japanese (B) encephalitis. Am J Trop Med Hyg 1973; 22: 524-34.
106. Hammon WM, Tigertt WD, Sather GE, Berge TO, Meiklejohn G: Epidemiologic studies of concurrent virgin epidemics of Japanese B encephalitis and of mumps on Guam, 1947-1948, with subsequent observations including dengue, through 1957. Am J Trop Med Hyg 1958; 7: 441-67.
107. Rhim JS, Hammon WM: Quantitative studies of Japanese B encephalitis virus in hamster kidney cell cultures. Proc Soc Exp Biol Med 1963; 112: 419-24.
108. Rohitayodhin S, Hammon WM: Development of attenuated strain of Japanese B encephalitis virus for possible use as a vaccine. Milit Med 1962; 127: 567-8.
109. Rohitayodhin S, Hammon WM: Studies on Japanese B encephalitis virus vaccines from tissue culture. J Immunol 1962; 89: 582-8.
110. Rohitayodhin S, Hammon WM: Studies on Japanese B encephalitis virus vaccines from tissue culture. II. Development of an attenuated strain of virus. J Immunol 1962; 89: 589-97.
111. Rohitayodhin S, Hammon WM: Studies on Japanese B encephalitis virus vaccines from tissue culture. III. Further selection and testing of attenuated virus lines from OCT-541. J Immunol 1962; 89: 823-33.
112. Singh B, Chang IC, Hammon WM: Semi-commercial-scale production of Japanese B encephalitis virus vaccines from tissue culture. Appl Microbiol 1973; 25: 945-51.
113. Singh B, Hammon WM: Studies on Japanese B encephalitis virus vaccines from tissue culture. XI. Immune mechanism and evaluation of the mouse challenge potency test. Appl Microbiol 1971; 21: 743-8.
114. Tigertt WD, Hammon WM, Berge TO, et al: Japanese B encephalitis; a complete review of experience on Okinawa 1945-1949. Am J Trop Med Hyg 1950; 30: 689-722.
115. Eckels KH, Putnak R: Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines. Adv Virus Res 2003; 61: 395-418.
116. Srivastava AK, Putnak JR, Lee SH, et al: A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. Vaccine 2001; 19: 4557-65.
117. McNeil JG, Lednar WM, Stansfield SK, Priez RE, Miller RN: Central European tick-borne encephalitis: assessment of risk for persons in the armed services and vacationers. J Infect Dis 1985; 152: 650-1.
118. Craig SC, Pittman PR, Lewis TE, et al: An accelerated schedule for tick-borne encephalitis vaccine: the American military experience in Bosnia. Am J Trop Med Hyg 1999; 61: 874-8.
119. Sanchez JL, Craig SC, Kohlhase K, Polyak C, Ludwig SL, Rumm PD: Health assessment of U.S. military personnel deployed to Bosnia-Herzegovina for Operation Joint Endeavor. Milit Med 2001; 166: 470-4.
120. Schmaljohn C, Custer D, VanderZanden L, Spik K, Rossi C, Bray M: Evaluation of tick-borne encephalitis DNA vaccines in monkeys. Virology 1999; 263; 166-74.
121. Schmaljohn CS: DNA Vaccines against tick-borne flaviviruses. U.S. Patent 6,258,788, July 10, 2001. Available at www.uspto.gov; accessed December 2004.
122. Schmaljohn C, Vanderzanden L, Bray M, et al: Naked DNA vaccines expressing the prM and E genes of Russian spring summer encephalitis virus and central European encephalitis virus protect mice from homologous and heterologous challenge. J Virol 1997; 71: 9563-9.
123. Peters CJ, Dalrymple JM: Alphaviruses. In Fields Virology, Ed 3, pp 713-59. Edited by Fields BN, Knipe DM, Howley PM. Philadelphia, Lippincott-Raven, 1996.
124. Sanchez JL, Takafuji ET, Lednar WM, et al: Venezuelan equine encephalomy-elitis: report of an outbreak associated with jungle exposure. Milit Med 1984; 149: 618-21.
125. Franck PT, Johnson KM: An outbreak of Venezuelan equine encephalomyelitis in Central America: evidence for exogenous source of a virulent virus subtype. Am J Epidemiol 1971; 94: 487-95.
126. Peters CJ, Olshaker M: Virus Hunter, pp 62-85. New York, Doubleday, 1997.
127. Oberste MS, Fraire M, Navarro R, et al: Association of Venezuelan equine encephalitis virus subtype IE with two equine epizootics in Mexico. Am J Trop Med Hyg 1998; 59: 100-7.
128. Oberste MS, Schmura SM, Weaver SC, and Smith JF: Geographic distribution of Venezuelan equine encephalitis virus subtype IE genotypes in Central America and Mexico. Am J Trop Med Hyg 1999; 60: 630-4.
129. Oberste MS, Weaver SC, Watts DM, Smith JF: Identification and genetic analysis of Panama-genotype Venezuelan equine encephalitis virus subtype ID in Peru. Am J Trop Med Hyg 1998; 58: 41-6.
130. Turell MJ, Jones JW, Sardelis MR, et al: Vector competence of Peruvian mosquitoes (Diptera: Culicidae) for epizootic and enzootic strains of Venezuelan equine encephalomyelitis virus. J Med Entomol 2000; 37: 835-9.
131. Turell MJ, Ludwig GV, Kondig J, Smith JF: Limited potential for mosquito transmission of genetically engineered, live-attenuated Venezuelan equine encephalitis virus vaccine candidates. Am J Trop Med Hyg 1999; 60; 1041-4.
132. Turell MJ, O'Guinn ML, Navarro R, Romero G, Estrada-Franco JG: Vector competence of Mexican and Honduran mosquitoes (Diptera: Culicidae) for enzootic (IE) and epizootic (IC) strains of Venezuelan equine encephalitis virus. J Med Entomol 2003; 40: 306-10.
133. Watts DM, Callahan J, Rossi C, et al: Venezuelan equine encephalitis febrile cases among humans in the Peruvian Amazon River region. Am J Trop Med Hyg 1998; 58: 35-40.
134. Watts DM, Lavera V, Callahan J, et al: Venezuelan equine encephalitis and Oropouche virus infections among Peruvian army troops in the Amazon region of Peru. Am J Trop Med Hyg 1997; 56: 661-7.
135. Hart MK, Lind C, Bakken R, Robertson M, Tammariello R, Ludwig GV: Onset and duration of protective immunity to IA/B and IE strains of Venezuelan equine encephalitis virus in vaccinated mice. Vaccine 2002; 20: 616-22.
136. Ludwig GV, Turell MJ, Vogel P, et al: Comparative neurovirulence of attenuated and non-attenuated strains of Venezuelan equine encephalitis virus in mice. Am J Trop Med Hyg 2001; 64: 49-55.
137. Steele KE, Davis KJ, Stephan K, Kell W, Vogel P, Hart MK: Comparative neurovirulence and tissue tropism of wild-type and attenuated strains of Venezuelan equine encephalitis virus administered by aerosol in C3H/HeN and BALB/c mice. Vet Pathol 1998; 35: 386-97.
138. Reed DS, Lind CM, Sullivan LJ, Pratt WD, Parker MD: Aerosol infection of cynomolgus macaques with enzootic strains of Venezuelan equine encephalitis viruses. J Infect Dis 2004; 189: 1013-7.
139. Vogel P, Abplanalp D, Kell W, et al: Venezuelan equine encephalitis in BALB/c mice: kinetic analysis of central nervous system infection following aerosol or subcutaneous inoculation. Arch Pathol Lab Med 1996; 120: 164-72.
140. Hart MK, Pratt W, Panelo F, Tammariello R, Dertzbaugh M: Venezuelan equine encephalitis virus vaccines induce mucosal IgA responses and protection from airborne infection in BALB/c, but not C3H/HeN mice. Vaccine 1997; 15: 363-9.
141. Hart MK: Prophylactic and therapeutic monoclonal antibodies. U.S. Patent 6,824,778, November 30, 2004. Available at www.uspto.gov: accessed December 2004.
142. Sutton LS, Brooke CC: Venezuelan equine encephalomyelitis due to vaccination in man. JAMA 1954; 155: 1473-6.
143. Burke DS, Ramsburg HH, Edelman R: Persistence in humans of antibody to subtypes of Venezuelan equine encephalomyelitis (VEE) virus after immunization with attenuated (TC-83) virus vaccine. J Infect Dis 1977; 136: 354-9.
144. Cole FE, Pedersen CE, Robinson DM, Eddy GA: Improved method for production of attenuated Venezuelan equine encephalomyelitis (TC-83 strain) vaccine. J Clin Microbiol 1976; 4: 460-2.
145. Davis NL, Willis LV, Johnston RE, Smith JF: cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof. U.S. Patent 5,185,440, February 9, 1993. Available at www.uspto.gov; accessed December 2004.
146. Johnston RE, Davis NL, Smith JL, Glieder FB: Attenuating mutations in Venezuelan equine encephalitis virus. U.S. Patent 5,505,947, April 9, 1996. Available at www.uspto.gov; accessed December 2004.
147. Pratt WD, Davis NL, Johnston RE, Smith JF: Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models. Vaccine 2003; 21: 3854-62.
148. Pushko P, Parker MD, Smith JF, Crise BJ: Live attenuated Venezuelan equine encephalitis vaccine. U.S. Patent 6,296.854, October 2, 2001. Available at www.uspto.gov; accessed December 2004.
149. Hart MK, Azarion M: Overcoming interference in alphavirus immune individuals. U.S. Patent 6,261,567, July 17, 2001. Available at www.uspto.gov; accessed December 2004.
150. Hart MK, Caswell-Stephan K, Bakken R, et al: Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate. Vaccine 2000; 18: 3067-75.
151. McClain DJ, Pittman PR, Ramsburg HH et al: Immunologic interference from sequential administration of live-attenuated alphavirus vaccines. J Infect Dis 1998; 177: 634-41.
152. Cole FE, May SW, Eddy GA: Inactivated Venezuelan equine encephalomyelitis vaccine prepared from attenuated (TC-83 strain) virus. Appl Microbiol 1974; 27: 150-3.
153. Edelman R, Ascher MS, Oster CN, Ramsburg HH, Cole FE, Eddy GA: Evaluation in humans of a new, inactivated vaccine for VEE virus (C-84). J Infect Dis 1979; 140: 708-15.
154. Pratt WD, Gibbs P, Pitt ML, Schmaljohn AL: Use of telemetry to assess vaccine-induced protection against parenteral and aerosol infections of Venezuelan equine encephalitis virus in non-human primates. Vaccine 1998; 16: 1056-64.
155. Pittman PR, Makuch RS, Mangiafico JA, Cannon TL, Gibbs PH, Peters CJ: Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine 1996; 14: 337-43.
156. Greenway TE, Eldridge JH, Ludwig G, et al: Enhancement of protective immune responses to Venezuelan equine encephalitis (VEE) virus with microencapsulated vaccine. Vaccine 1995; 13: 1411-20.
157. Hodgson LA, Ludwig GV, Smith JF: Expression, processing, and immunogenicity of the structural proteins of Venezuelan equine encephalitis virus from recombinant baculovirus vectors. Vaccine 1999; 17: 1151-60.
158. Riemenschneider J, Garrison A, Geisbert J, et al: Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus, and Venezuelan equine encephalitis virus. Vaccine 2003; 21: 4071-80.
159. Davis NL, Brown KW, Greenwald GF, et al: Attenuated mutants of Venezuelan equine encephalitis virus containing lethal mutations in the PE2 cleavage signal combined with a second-site suppressor mutation in El. Virology 1995; 212: 102-10,
160. Davis NL, Powell N, Greenwald GF, et al: Attenuating mutations in the E2 glycoprotein gene of Venezuelan equine encephalitis virus: construction of single and multiple mutants in a full-length cDNA clone. Virology 1991; 183: 20-31.
161. Davis NL, Willis LV, Smith JF, Johnston RE: In vitro synthesis of infectious Venezuelan equine encephalitis virus RNA from a cDNA clone: analysis of a viable deletion mutant, Virology 1989; 171: 189-204.
162. Oberste MS, Parker MD, Smith JF: Complete sequence of Venezuelan equine encephalitis virus subtype IE reveals conserved and hypervariable domains within the C terminus of nsP3. Virology 1996; 219: 314-20.
163. Johnston RE, Davis NL, Smith JF, Pushko P, Parker M, Ludwig G: Alphavirus RNA replicon systems. U.S. Patent 5,792,462, August 11, 1998. Available at www.uspto.gov; accessed December 2004.
164. Johnston RE, Davis NL, Smith JF, Grieder FB: Method of inducing an immune response with a live Venezuelan equine encephalitis virus expressing a heterologous immunogen. U.S. Patent 5,643,576, July 1, 1997. Available at www.uspto.gov; accessed December 2004.
165. Parker MD, Smith JL, Crise BJ, Oberste MS, Schmura SM: Live attenuated virus vaccines for Western equine encephalitis virus. Eastern equine encephalitis virus, and Venezuelan equine encephalitis virus IE and IIIA variants. U.S. Patent 6,261,570, July 17, 2001. Available at www.uspto.gov: accessed December 2004.
166. Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, Smith JF: Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 1997; 239: 389-401.
167. Williams JE, Young OP, Watts DM, Reed TJ: Wild birds as Eastern (EEE) and Western (WEE) equine encephalitis sentinels. J Wildl Dis 1971; 7: 188-94.
168. Clark GG, Dein FJ, Crabbs CL, Carpenter JW, Watts DM: Antibody response of sandhill and whooping cranes to an Eastern equine encephalitis (EEE) virus vaccine. J Wildl Dis 1988; 23: 539-44.
169. Olsen GH, Turell MJ, Pagac BB: Efficacy of Eastern equine encephalitis immunization in whooping cranes. J Wildl Dis 1997; 33: 312-15.
170. Cole FE: Inactivated Eastern equine encephalomyelitis vaccine propagated in rolling-bottle cultures of chick embryo cells. Appl Microbiol 1971; 22: 842-5.
171. Maire LF, McKinney RW, Cole FE: An inactivated Eastern equine encephalomyelitis vaccine propagated in chick-embryo cell culture. I. Production and testing. Am J Trop Med Hyg 1970; 19: 119-22.
172. Meadors G, Pittman PR, Makuch RS, Cannon TL, Mangiafico J, Gibbs PH: Eastern equine encephalitis virus vaccine: an analysis of 16 years of experience with the safety and immunogenicity at a research institute. Presented at the 41st Annual Meeting of the American Society of Tropical Medicine and Hygiene, Seattle, WA, 1992.
173. Schoepp RJ, Smith JF, Parker MD: Recombinant chimeric Western and Eastern equine encephalitis viruses as potential vaccine candidates. Virology 2002; 302: 299-309.
174. O'Guinn ML, Lee JS, Kondig JP, Fernandez R, Carbajal F: Field detection of Eastern equine encephalitis virus in the Amazon Basin region of Peru using reverse transcription-polymerase chain reaction adapted for field identification
175. Netolitzky DJ, Schmaltz FL, Parker MD, et al: Complete genomic RNA sequence of Western equine encephalitis virus and expression of the structural genes. J Gen Virol 2000; 81: 151-9.
176. Mitchell CJ, Monath TP, Sabattini MS, et al: Arbovirus isolations from mosquitoes collected during and after the 1982-1983 epizootic of Western equine encephalitis in Argentina. Am J Trop Med Hyg 1987; 36: 107-13.
177. Monath TP, Sabattini MS, Pauli R et al: Arbovirus investigations in Argentina, 1977-1980. IV. Serologic surveys and sentinel equine program. Am J Trop Med Hyg 1985; 34: 966-75.
178. Anderson BA: Focal neurologic signs in Western equine encephalitis. Can Med Assoc J 1984; 130: 1019-21.
179. Bia FJ, Thornton GF, Main AJ, Fong CK, Hsiung GD: Western equine encephalitis mimicking herpes simplex encephalitis. JAMA 1980; 244: 367-9.
180. White DP, Miller F, Erickson RW: Sleep apnea and nocturnal hypoventilation after Western equine encephalitis. Am Rev Respir Dis 1983; 127: 132-3.
181. Chang MH, Glynn MK, Groseclose SL: Endemic, notifiable bioterrorism-related diseases. United States, 1992-1999. Emerg Infect Dis 2003; 9: 556-64.
182. Chanock RM, Sabin AB: The hemagglutinin of Western equine encephalitis virus: recovery, properties and use for diagnosis. J Immunol 1954; 73: 337-51.
183. Chanock RM, Sabin AB: Hemagglutinins of the St. Louis and Western equine encephalitis viruses: isolation, properties, and use for diagnosis and epidemiologic survey. Am J Dis Child 1952; 84: 628-9.
184. Watts DM, Tammariello RF, Dalrymple JM, Eldridge BF, Russell PK, Top FJ: Experimental infection of vertebrates of the Pocomoke Cypress Swamp, Maryland, with Keystone and Jamestown Canyon viruses. Am J Trop Med Hyg 1979; 28: 344-50.
185. Watts DM, Williams JE: Experimental Infection of Bobwhite Quail (Colinus virginianus) with Western equine encephalitis (WEE) virus. J Wildl Dis 1972; 8: 44-8.
186. Williams JE, Watts DM, Young OP, Reed TM: Transmission of Eastern (EEE) and Western (WEE) equine encephalitis viruses to Bobwhite sentinels in relation to density of Culiseta melanura mosquitoes. Mosq News 1972; 32: 188-92.
187. Jahrling PB, Hesse RA, Anderson AO, Gangemi JD: Opsonization of alphaviruses in hamsters. J Med Virol 1983; 12: 1-16.
188. Long MC, Nagata LP, Ludwig GV, et al: Construction and characterization of monoclonal antibodies against western equine encephalitis virus. Hybridoma 2000; 19: 121-7.
189. Hayes CG: Variations in biological properties of geographic strains of Western equine encephalomyelitis virus before and after passage in Culex tarsalis and Culiseta melanura. Acta Virol 1978; 22: 401-9.
190. Hayes CG: Vector competence of colonized Culiseta melanura (Diptera: Culicidae) for Western equine encephalomyelitis virus. J Med Entomol 1979; 15: 253-8.
191. Hayes CG, Wallis RC: Ecology of Western equine encephalomyelitis in the eastern United States. Adv Virus Res 1977; 21: 37-83.
192. Wallis RC, Hayes CG: Evaluation of the epidemic potential of Western equine encephalitis virus in the northeastern United States. Yale J Biol Med 1976; 49: 439-45.
193. Williams JE, Young OP, Watts DM: Relationship of density of Culiseta melanura mosquitoes to infection of wild birds with Eastern and Western equine encephalitis viruses. J Med Entomol 1974; 11: 352-4.
194. Cannon TL, Makuch RS, Gibbs PH, Mangiafico J, Pittman PR: A 15-year review (1976-1990) of the safety and immunogenicity of Western equine encephalitis, Formalin-inactivated vaccine. Presented at the 41st Annual Meeting of the American Society of Tropical Medicine and Hygiene, Seattle, WA, 1992.
195. Cole FE, McKinney RW: Use of hamsters of potency assay of Eastern and Western equine encephalitis vaccines. Appl Microbiol 1969; 17: 927-8.
196. Robinson DM, Herman S, Lowenthal JP: Mouse potency assay for Western equine encephalomyelitis vaccines. Appl Microbiol 1972; 23: 104-7.
197. Turell MJ, O'Guinn ML, Parker MD: Limited potential for mosquito transmission of genetically engineered, live-attenuated Western equine encephalitis virus vaccine candidates. Am J Trop Med Hyg 2003; 68: 218-21.
198. Campbell GL, Marfin AA, Lanciotti RS, Gubler DJ: West Nile virus. Lancet Infect Dis 2002; 2: 519-29.
199. Johnson RT, Irani DN: West Nile virus encephalitis in the United States. Curr Neurol Neurosci Rep 2002; 2: 496-500.
200. Hayes CG: West Nile virus: Uganda, 1937, to New York City. 1999. Ann N Y Acad Sci 2001; 951: 25-37.
201. Hamilton PK, Taylor RM: Report of clinical case of West Nile virus infection probably acquired in the laboratory. Am J Trop Med Hyg 1954; 3: 51-3.
202. Hurlbut HS, Rizk F, Taylor RM, Work TH: A study of the ecology of West Nile virus in Egypt. Am J Trop Med Hyg 1956; 5: 579-620.
203. Taylor RM, Hurlbut HS, Dressier HR, Spangler EW, Thrasher D: Isolation of West Nile virus from Culex mosquitoes. J Egypt Med Assoc 1953; 36: 199-208.
204. Work TH, Hurlbut HS, Taylor RM: Indigenous wild birds of the Nile delta as potential West Nile virus circulating reservoirs. Am J Trop Med Hyg 1955; 4: 872-88.
205. Work TH, Hurlbut HS, Taylor RM: Isolation of West Nile virus from hooded crow and rock pigeon in the Nile delta. Proc Soc Exp Biol Med 1953; 84: 719-22.
206. Darwish MA, Feinsod FM, Scott RM, et al: Arboviral causes of non-specific fever and myalgia in a fever hospital patient population in Cairo, Egypt. Trans R Soc Trop Med Hyg 1987; 81: 1001-3.
207. Corwin A, Habib M, Olson J, Scott D, Ksiazek T, Watts DM: The prevalence of arboviral, rickettsial, and Hantaan-like viral antibody among schoolchildren in the Nile river delta of Egypt. Trans R Soc Trop Med Hyg 1992; 86: 677-9.
208. Turell MJ, Morrill JC, Rossi CA, et al: Isolation of West Nile and sindbis viruses from mosquitoes collected in the Nile Valley of Egypt during an outbreak of Rift Valley fever. J Med Entomol 2002; 39: 248-50.
209. Steele KE, Linn MJ, Schoepp RJ, et al: Pathology of fatal West Nile virus infections in native and exotic birds during the 1999 outbreak in New York City, New York. Vet Pathol 2000; 37: 208-24.
210. Lanciotti RS, Roehrig JT, Deubel V, et al: Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science 1999; 286: 2333-7.
211. Turell MJ, Sardelis MR, O'Guinn MS, Dohm DJ: Potential vectors of West Nile virus in North America, in Japanese encephalitis and West Nile viruses. In Current Topics in Microbiology and Immunology, pp 241-52. Edited by Mackenzie JS, Barrett ADT, Deubel V. Berlin, Springer-Verlag, 2002.
212. Witt CJ, Brundage M, Cannon C, et al: Department of Defense West Nile virus surveillance in 2002. Milit Med 2004; 169: 421-8.
213. Ahmed T, Hayes CG, Baqar S: Comparison of vector competence for West Nile virus of colonized populations of Culex tritaeniorhynchus from southern Asia and the Far East. Southeast Asian J Trop Med Public Health 1979; 10: 498-504.
214. Baqar S, Hayes C, Murphy JR, Watts DM: Vertical transmission of West Nile virus by Culex and Aedes species mosquitoes. Am J Trop Med Hyg 1993; 48: 757-62.
215. Hadfield TL, Turell M, Dempsey MP, David J, Park EJ: Detection of West Nile virus in mosquitoes by reverse transcriptase-polymerase chain reaction. Mol Cell Probes 2001; 15: 147-50.
216. Porter KR, Summers PL, Dubois D, et al: Detection of West Nile virus by the polymerase chain reaction and analysis of nucleotide sequence variation. Am J Trop Med Hyg 1993; 48: 440-6.
217. Ran J, Dave K, Emmerich E, et al: Wicking assays for the rapid detection of West Nile and St. Louis encephalitis viral antigens in mosquitoes (Diptera: Culicidae). J Med Entomol 2003; 40: 95-9.
218. Kanesa-Thasan N, Putnak JR, Mangiafico JA, Saluzzo JE, Ludwig GV: Short report: absence of protective neutralizing antibodies to West Nile virus in subjects following vaccination with Japanese encephalitis or dengue vaccines. Am J Trop Med Hyg 2002; 66: 115-16.
219. Turell MJ, Bunning M, Ludwig GV, et al: Efficacy of a DNA vaccine for protecting fish crows (Corvus ossifragus) from fatal West Nile virus infection. Emerg Infect Dis 2003; 9: 1077-81.
220. Arroyo J, Miller C, Catalan J, et al: ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J Virol 2004; 78: 12497-507.
221. Pletnev AG, Putnak R, Speicher J, Wagar EJ, Vaughn DW: West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy. Proc Natl Acad Sci U S A 2002; 99: 3036-41.
222. Rizzolo J, Osborne DV: Current rabies problems of military medicine in SEATO areas. Milit Med 1962; 127: 195-204.
223. Dehner LP: Human rabies encephalitis in Vietnam. Ann Intern Med 1970; 72: 375-8.
224. Tice AW: Post-exposure use of the new human diploid cell (rabies) vaccine at Clark Air Base. Aviat Space Environ Med 1980; 51: 923-5.
225. Fester JM: Public health aspects of rabies. Aviat Space Environ Med 1975; 46: 1194-5.
226. Armed Forces Epidemiological Board: Recommendation with respect to the use of hyperimmune anti-rabies serum (memo dated June 14. 1955). Available at www.ha.osd.mil/afeb/1955/1955-01.pdf; accessed December 2004.
227. Armed Forces Epidemiological Board: Use of duck-embryo rabies vaccine (memo dated December 14, 1960). Available at www.ha.osd.mil/afeb/1960/1960-02. pdf; accessed December 2004.
228. Koch FJ, Sagartz JW, Davidson DE, Lawhaswasdi K: Diagnosis of human rabies by the cornea test. Am J Clin Pathol 1975; 63: 509-15.
229. Warner RD: Occurrence and impact of zoonoses in pet dogs and cats at U.S. Air Force bases. Am J Public Health 1984; 74: 1239-43.
230. Dembert ML, Lawrence WB, Weinberg WG, et al: Epidemiology of human rabies post-exposure prophylaxis at the U.S. Naval Facility, Subic Bay, Philippines. Am J Public Health 1985; 75: 1440-1.
231. Croft A, Archer R: Dog bites in Bosnia. Br J Gen Pract 1997; 47: 435-7.
232. Hayne ST, Heil JR, Moeller RB: Rabies: the re-emergence of a dreaded disease. Milit Med 1983; 148: 903-7.
233. Lemon SM, Thaul S, Fisseha S, O'Maonaigh HC: Protecting Our Forces: Improving Vaccine Acquisition and Availability in the U.S. Military. Washington, DC, National Academic Press, 2002.